Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE ...

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vaccines in late 2020 and part of 2021 ...

Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks very cheap compared with historical levels," Yee said.

In this article, we will look at the 10 Biotech Stocks Screaming a Buy. The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott ...

Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how their treatments fare in Food & Drug Administration clinical ...

This is an amazing week to consider biotech stocks. Big news by the U.S. Food & Drug Administration (which we’ll get to momentarily) shows the benefits and outsized gains you can enjoy by ...

While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.

Rachael Bushey and Jennifer Porter of Troutman Pepper discuss strategies for biotech companies in gearing up for success when the stock market rebounds.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock is finally on the rebound, after a long-term pullback from its Aug. 27, record high of $1,211.20.